Duchenne MD Therapy Trial: Positive Data for Pediatric Patients
Regenxbio reported positive interim safety and efficacy data for RGX-202 in the Phase I/II Affinity Duchenne trial, showing promising results for patients with Duchenne muscular dystrophy aged 1 to 11.